

31 August 2026

2026 ANNUAL GENERAL MEETING – KEY DATES

In accordance with ASX Listing Rule 3.13.1, Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) is pleased to announce the 2026 annual general meeting has been scheduled for 2.00pm (WST) on Thursday, 12 November 2026 at the offices of Stantons International at Level 2, 40 Kings Park Road, West Perth, Western Australia.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Thursday, 24 September 2026, being 35 business days before the date of the 2026 annual general meeting. Nominations must be received at the Company’s registered office no later than 5.00pm (WST) on Thursday, 24 September 2026.

Further information on the Annual General Meeting will be provided in the Notice of Annual General Meeting which will be released to ASX on or before Friday, 9 October 2026.

This announcement was authorised for release to the ASX by the Board of Emyria Limited.

For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact:

Greg Hutchinson

Executive Chair

1300 436 363 | investors@emyria.com



Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

informs

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.